Karyopharm Therapeutics Inc (KPTI) Given Average Recommendation of “Buy” by Brokerages

Karyopharm Therapeutics Inc (NASDAQ:KPTI) has received a consensus rating of “Buy” from the eleven ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $18.50.

A number of research firms recently issued reports on KPTI. BidaskClub upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 9th. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. ValuEngine upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 8th. Cantor Fitzgerald restated a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, January 25th. Finally, HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, December 12th.

Karyopharm Therapeutics (KPTI) traded up $0.97 during midday trading on Wednesday, reaching $14.17. 564,500 shares of the company were exchanged, compared to its average volume of 224,589. The firm has a market capitalization of $653.84, a P/E ratio of -5.35 and a beta of 4.11. Karyopharm Therapeutics has a 52 week low of $7.48 and a 52 week high of $14.85.

In other Karyopharm Therapeutics news, CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $9.16, for a total value of $91,600.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares in the company, valued at $4,782,829.88. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Christopher Brett Primiano sold 27,042 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $10.28, for a total transaction of $277,991.76. Following the completion of the transaction, the senior vice president now owns 11,381 shares of the company’s stock, valued at approximately $116,996.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,542 shares of company stock valued at $819,692. Insiders own 14.71% of the company’s stock.

Several institutional investors have recently modified their holdings of KPTI. Teacher Retirement System of Texas acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter worth about $115,000. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics during the second quarter worth about $136,000. Voya Investment Management LLC increased its stake in shares of Karyopharm Therapeutics by 42.1% during the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Karyopharm Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after purchasing an additional 5,586 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Karyopharm Therapeutics by 33.6% during the second quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock worth $255,000 after purchasing an additional 7,099 shares in the last quarter. Institutional investors and hedge funds own 57.85% of the company’s stock.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/karyopharm-therapeutics-inc-kpti-given-average-recommendation-of-buy-by-brokerages.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply